Ageng Aji Milendi, Evi Umayah Ulfa, Mark Niño B. Melgo, Afifah Machlaurin
Cancer is a leading cause of death worldwide and is associated with significant global economic losses. In this context, several innovations are introduced in the treatments but cost-effectiveness remains controversial. Artificial intelligence (AI) has massively assisted in the diagnosis, prognosis, and determination of cancer management. Therefore, this research aimed to systematically review the implementation of AI and cost-effectiveness in cancer treatment. The analysis followed PRISMA guidelines and used the PubMed database. The search strategy was conducted up to 2 September 2023 using three main keywords, namely “Cost-effectiveness analysis”, “Cancer”, and “Artificial intelligence”. From 1746 retrieved articles, a total of 11 were included in the analysis. The results showed that there were two types of AI interventions in cancer, namely screening (n = 6; 55%) and surgery (n = 5; 45%). Meanwhile, prostate cancer was the most frequently analyzed (n = 3; 27%). Cost-effectiveness analysis reported that the implementation of AI was cost-effective (n=5, 46%), particularly in cancer screening intervention. AI intervention in screening was the most cost-effective strategy. In contrast, AI implementation in surgery showed inconsistent results, with limited research addressing the economic evaluation. Copyright © 2026 by Indonesian Journal of Pharmacy (IJP).
Faculty of Pharmacy, Jember University, Sumbersari, East Java, Jember, 68121, Indonesia; Magister Pharmacy, Faculty of Pharmacy, Jember University, Sumbersari, East Java, Jember, 68121, Indonesia; Drug Utilization Research Group, Department of Clinical and Community Pharmacy, Faculty of Pharmacy, Jember University, Sumbersari, East Java, Jember, 68121, Indonesia; Department of Pharmacy, School of Health Care Professions, University of San Carlos, Nasipit, Talamban, Cebu, 6000, Philippines
